What Entod Research Cell UK Ltd does

Entod Research Cell UK Ltd is a UK-based, privately held specialty healthcare company (incorporated in England & Wales, company no. 7418222) operating as a formulation research and development organisation focused on ophthalmic and skincare fields. Founded in 1977 by pharmaceutical entrepreneur Nikkhil K Masurkar and originating as a strategic spin-off from ENTOD Pharmaceuticals Ltd — which it still retains as a technical partner — the company designs, develops and supplies eye care, eye beauty and skincare products across five categories: ocular diagnostics, dry eye therapies and lid hygiene, eye supplements, eye beauty and speciality skincare, and dry-mouth (artificial saliva) products. Its core proprietary asset is Stabilised Oxychloro Complex (SOC), an ophthalmic preservative developed and produced in collaboration with Medisearch Laboratories (Bombay) Pvt Ltd at an exclusive laboratory facility; SOC meets European Pharmacopeia Criteria B for efficacy and is validated under ISO 11981, ISO 10993-5 and ISO 10993-10 for contact-lens compatibility, non-cytotoxicity and non-irritation. The portfolio is marketed through three consumer sub-brands — I-Dew Eye Care, Lashfactor and Vasuki — alongside B2B supply of SOC to pharmaceutical formulators worldwide.

The company is quality-certified to ISO 13485:2016, ISO 9001:2015, WHO GMP and CE for medical devices and eye drops, supporting distribution to over 67 countries worldwide through a dedicated network spanning 55+ countries across 3 continents. Revenue mechanics combine one-time product sales across healthcare consumer SKUs with B2B supply of SOC as an ingredient, complemented by a General Trading Division handling Engineering, Oil & Gas and Chemicals transactions across 80+ countries on a transaction-fee basis. Go-to-market is enterprise field-sales driven through distributor and partner networks rather than direct consumer channels, with digital presence limited to corporate and sub-brand websites plus downloadable product brochures. Revenue figures are not publicly disclosed and the company has no recorded institutional funding or M&A history, operating as a founder-led private entity with a globally distributed but UK-headquartered governance structure.

Name

Entod Research Cell UK Ltd

Legal name

Entod Research Cell UK Ltd

Website

https://entodresearchcell.com

Company type

Private

Founded year

1977

Operating status

Operating

Headcount range

1–10 employees

Short description

UK-based specialty healthcare company (founded 1977) developing and distributing ophthalmic diagnostics, dry-eye therapies, eye beauty and skincare products globally via its proprietary SOC preservative, sub-brands I-Dew/Lashfactor/Vasuki, and a 67+ country distribution network.

Ownership category

akta.pro rank

Product category

Ophthalmic Pharmaceuticals & Eye Care

NAICS

Ophthalmic Goods Manufacturing (339115), Ophthalmic Goods Merchant Wholesalers (423460), Ophthalmic Goods Merchant Wholesalers (42346), Cosmetics, Beauty Supplies, and Perfume Retailers (456120)

SIC

Pharmaceutical Preparations (2834), Ophthalmic Goods (3851)

akta.pro primary industry

Ophthalmology Specialty Pharmaceuticals (HLAIACAK)

akta.pro secondary industries

Ophthalmology Pharmaceuticals (HLAIAAAL), Dermatology Specialty Pharmaceuticals (HLAIACAL), Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK), Dermocosmetics & Medical-Grade Skincare (CRABAAAF)

Keywords

• Ophthalmic pharmaceuticals
• Eye care products
• Skincare formulations
• Ophthalmic preservatives
• Dry eye therapies

Headquarters

HQ city

London, Greater London

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Eye Care Products: Sale of eye care products including eye drops, ocular diagnostics, dry eye therapies and eye supplements
2. Eye Beauty & Skincare Products: Consumer healthcare and wellness products including skincare and eye beauty products
3. SOC (Stabilised Oxychloro Complex): Development, production and supply of ophthalmic preservative as laboratory material for incorporation into eye drop formulations worldwide
4. General Trading Division: Trading in Engineering, Oil & Gas and Chemicals business segments spanning 80+ countries

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Entod Research Cell UK Ltd designs, develops, and supplies ophthalmic and skincare healthcare products, with a core offering of the proprietary Stabilised Oxychloro Complex (SOC) preservative for incorporation into eye drop formulations worldwide. Its consumer-facing portfolio spans ocular diagnostics, dry eye therapies and lid hygiene, eye supplements, eye beauty and speciality skincare, and dry mouth (artificial saliva) products marketed under the I-Dew Eye Care, Lashfactor, and Vasuki sub-brands. The company also operates a General Trading Division handling Engineering, Oil & Gas and Chemicals business segments.

Product overview

Entod Research Cell UK Ltd is a specialty research-based healthcare company operating as a formulation research and development organization specializing in ophthalmic and skincare fields. The company offers a unified portfolio centered on five product categories: Ocular Diagnostics, Dry Eye Therapies & Lid Hygiene, Eye Supplements, Eye Beauty & Speciality Skincare, and Dry Mouth (Artificial Saliva). Their core proprietary product is Stabilised Oxychloro Complex (SOC), an ophthalmic preservative developed in partnership with Medisearch Laboratories, which serves as the foundational technology incorporated into eye drop formulations worldwide. The portfolio also includes three consumer-facing sub-brands—I-Dew Eye Care (eye care), Lashfactor (eye beauty), and Vasuki (skincare/wellness)—representing distinct market positions within the broader eye care, eye beauty, and skincare market. The company provides end-to-end formulation development support for integrating SOC into ophthalmic formulations.

Differentiator

Problem solved

Functional benefit

Brands

• I-Dew Eye Care: Eye care brand for ocular diagnostics and dry eye therapies
• Lashfactor
• Vasuki

Products and services

• Stabilised Oxychloro Complex (SOC)

Quantifiable outcome

• SOC meets European Pharmacopeia Criteria B for efficacy of preservatives for ophthalmic use
• +3 more outcomes

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Medisearch Laboratories (Bombay) Pvt LtdcoreStrategic or Co-development PartnerInternational research partner collaborating on development, production and supply of Stabilised Oxychloro Complex (SOC) ophthalmic preservative. SOC is developed and produced at an exclusive state-of-the-art laboratory facility run by the research partners.
• ENTOD Pharmaceuticals LtdcoreStrategic or Co-development PartnerTechnical partner from which ENTOD Research Cell UK originated as a strategic spin-off. Products are manufactured using technology mastered by the laboratories of one of the world's leading research-based speciality eye & skincare companies. Company retains ENTOD Pharmaceuticals as technical partner.
• ENTOD BeautyminorOthersAssociated business with separate brand website entodbeauty.com

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Alcon: World's largest eye-care device and pharmaceutical company with leading dry-eye, surgical, and OTC eye-drop franchises; overlaps with ERC UK on ophthalmic pharmaceuticals and consumer eye-care distribution.
• AbbVie (Allergan Aesthetics / Eye Care): Owns the former Allergan ophthalmology franchise (Refresh, Lumigan, Restasis) — a leading specialty ophthalmic pharma competitor that ERC UK's dry-eye and ocular-surface products directly contend with globally.
• Bausch + Lomb: Global ophthalmic goods manufacturer with a broad portfolio of eye drops, dry-eye therapies, lid hygiene, and contact lens care — directly comparable across ERC UK's ocular diagnostics, dry eye, and ophthalmic preservative categories.

Emerging players

• Nicox: Clinical-stage ophthalmic company developing preservative-free and nitric-oxide-based eye therapies — a smaller emerging competitor in the ophthalmic preservative and dry-eye space.
• NovaBay Pharmaceuticals: Specialty pharma developing ophthalmic products based on its proprietary neutralized hypochlorous acid (Aganocide) platform — a chemistry-adjacent emerging player to ERC UK's SOC preservative technology.

Direct peers

• Scope Ophthalmics: Specialty dry-eye and lid-hygiene company marketing products such as Thea Blephagel/eyelid hygiene ranges in international markets — directly comparable to ERC UK's lid hygiene and dry eye therapy positioning.
• Théa Pharmaceuticals: European specialty ophthalmic company with a preservative-free and lid-hygiene focus, including preservative alternatives — closely comparable to ERC UK's SOC preservative and dry-eye/lid-hygiene portfolio.
• URSAPHARM: German specialty ophthalmic company known for hyaluronic acid-based eye drops and preservative-conscious formulations — a like-for-like European specialty competitor to ERC UK's I-Dew line.
• Similasan: Consumer eye-care brand selling OTC dry eye, allergy, and lid-care products across multiple countries — comparable to ERC UK's I-Dew and Vasuki consumer sub-brands in OTC eye-care retail.
• Santen Pharmaceutical: Japan-based specialty ophthalmology pharma focused on dry eye, glaucoma, and ocular surface disease — a direct comparable for ERC UK's ophthalmic specialty pharmaceutical and dry-eye therapy positioning.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/ercukltd

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Entod Research Cell UK Ltd